World's Best Scientists 2026 revealed!
Antonio Palumbo

Antonio Palumbo

Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
120
Citations
77129
World Ranking
3671
National Ranking
105

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Antonio Palumbo is affiliated with the University of Turin in Italy. Their primary research intersects multiple disciplines within life sciences, focusing extensively on medicine, biochemistry, genetics, and molecular biology.

The scientist's scholarly output includes work published in notable venues such as Clinical Lymphoma Myeloma & Leukemia. Their research contributions encompass fields and subfields including:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology
  • Hematology
  • Molecular Biology
  • Oncology

Antonio Palumbo's research topics center around:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Peptidase Inhibition and Analysis

Among their recent publications is the paper titled "Maintenance Therapy with Belantamab, Pomalidomide and Dexamethasone in High-risk Myeloma Patients: A Phase 2 Study with a Safety Run-in - Interim Analysis", published in 2025 in Clinical Lymphoma Myeloma & Leukemia.

Their frequent coauthors include Ajay K. Nooka, Nisha S. Joseph, Richa Parikh, Vikas A. Gupta, and Craig C. Hofmeister. This collaboration indicates involvement in multi-author studies likely related to the clinical and molecular aspects of hematologic malignancies.

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

    Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

    Antonio Palumbo;Asher Chanan-Khan;Katja Christina Weisel;Ajay K Nooka

  • Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo

  • Targeting CD38 with daratumumab monotherapy in multiple myeloma

    Henk M Lokhorst;Torben Plesner;Jacob P Laubach;Hareth Nahi

  • Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Philippe Moreau;Tamás Masszi;Norbert Grzasko;Nizar J Bahlis

  • Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

    Michele Cavo;Paola Tacchetti;Francesca Patriarca;Maria Teresa Petrucci

  • Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    S. Vincent Rajkumar;Jean Luc Harousseau;Brian Durie;Kenneth C. Anderson

  • Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

    Antonio Palumbo;Sara Bringhen;Tommaso Caravita;Emanuela Merla

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson

  • Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy

  • Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

    A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel

  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    R A Kyle;B G M Durie;S V Rajkumar;O Landgren

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

    Antonio Palumbo;Roman Hajek;Michel Delforge;Martin Kropff

  • Autologous transplantation and maintenance therapy in multiple myeloma

    Antonio Palumbo;Federica Cavallo;Francesco Di Raimondo

Frequent Co-Authors

Mario Boccadoro
Mario Boccadoro University of Turin
Michele Cavo
Michele Cavo University of Bologna
Maria Teresa Petrucci
Maria Teresa Petrucci Sapienza University of Rome
Pellegrino Musto
Pellegrino Musto University of Bari Aldo Moro
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Roman Hájek
Roman Hájek University of Ostrava
Paolo Corradini
Paolo Corradini University of Milan
Federica Cavallo
Federica Cavallo University of Turin
Heinz Ludwig
Heinz Ludwig University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medicine or healthcare but seeking alternative or complementary pathways, online degrees offer flexibility and affordability. Many respected institutions now offer programs that can jumpstart a rewarding career in health services.

For example, an him associate degree online prepares students for roles organizing and managing health information data. If you're considering working behind the scenes in healthcare, explore how much does it cost to become a medical coder and discover programs designed to equip you for medical billing and coding positions. These roles are vital for maintaining patient records and processing insurance claims.

Nursing remains one of the most in-demand fields. Those looking to advance can find the cheapest np programs online to become nurse practitioners, while aspiring nurses can find affordable online nursing programs for their initial training. Online studies can streamline your entry into these dynamic healthcare professions, offering a path that suits different timelines and budgets.

Best Scientists Citing Antonio Palumbo

Trending Scientists